Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas (Q71574198)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

title

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

main subject

phase II clinical trial

1 reference

metastatic adenocarcinoma

inferred from title

1 reference

1 reference

R M Scher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

R Kosierowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

C Lusch

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

R Alexander

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

S Fox

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

I Redei

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

F Green

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

B Raskay

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

K Amfoh

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

P F Engstrom

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

P J O'Dwyer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

publication date

1 January 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

19 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

page(s)

347-354

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

19 October 2019

cites work

1 reference

12 December 2020

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

1 reference

12 December 2020

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

DNA topoisomerase poisons as antitumor drugs

1 reference

12 December 2020

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

12 December 2020

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer

1 reference

12 December 2020

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

12 December 2020

The current status of camptothecin analogues as antitumor agents

1 reference

12 December 2020

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

1 reference

12 December 2020

Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells

1 reference

12 December 2020

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

12 December 2020

Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells

1 reference

12 December 2020

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

12 December 2020

Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

1 reference

12 December 2020

1 reference

12 December 2020

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly

1 reference

12 December 2020

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

12 December 2020

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00873143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8824355%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference